Won Tae Kim

List of Publications by Year
in descending order

62 papers	**825** citations	516710 **16** h-index
63 all docs	**63** docs citations	**63** times ranked

642732 **23** g-index
1434 citing authors

#	Article	IF	Citations
1	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	2.3	5
2	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	2.0	3
3	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	2
4	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Letters, 2021, 499, 137-147.	7.2	42
5	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	1.6	12
6	A high basal metabolic rate is an independent predictor of stone recurrence in obese patients. Investigative and Clinical Urology, 2021, 62, 195.	2.0	4
7	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	2.0	2
8	Collagen typeÂVIâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	3.3	21
9	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. BMC Urology, 2021, 21, 85.	1.4	1
10	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	2.0	14
11	Nutritional status assessed by the Controlling Nutritional Status (CONUT) score as a predictor of recurrence of urolithiasis. Investigative and Clinical Urology, 2021, 62, 553.	2.0	2
12	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. Investigative and Clinical Urology, 2021, 62, 545.	2.0	6
13	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	4.1	7
14	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	2.0	19
15	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	2.5	24
16	Effects of poloxamerâ€based thermoâ€sensitive solâ€"gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, singleâ€blinded, randomised controlled trial. BJU International, 2020, 125, 160-167.	2.5	7
17	Advances in urinary biomarker discovery in urological research. Investigative and Clinical Urology, 2020, 61, S8.	2.0	22
18	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	1.8	9

#	Article	IF	Citations
19	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	2.0	7
20	For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects. International Neurourology Journal, 2019, 23, 5-12.	1.2	6
21	Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. International Urology and Nephrology, 2019, 51, 1129-1135.	1.4	8
22	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	1.9	12
23	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array–based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	2.6	6
24	Urinary cell–free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	5.1	30
25	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	1.6	11
26	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	2.5	17
27	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	2.0	2
28	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	1.9	8
29	The association of benign prostatic hyperplasia with lower urinary tract stones in adult men: A retrospective multicenter study. Asian Journal of Urology, 2018, 5, 118-121.	1.2	11
30	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	2.5	19
31	Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget, 2018, 9, 7961-7974.	1.8	9
32	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	2.0	18
33	Metabolic Characteristics and Risks Associated with Stone Recurrence in Korean Young Adult Stone Patients. Journal of Endourology, 2017, 31, 806-811.	2.1	7
34	Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncology Letters, 2017, 14, 3817-3824.	1.8	29
35	Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. Journal of Urology, 2017, 198, 1340-1345.	0.4	2
36	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 2017, 14, 2468-2474.	1.8	6

#	Article	IF	Citations
37	Angiopoietin-like protein 4 potentiates DATS-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; involvement of G_2/M-phase cell cycle arrest, signaling pathways, and transcription factors-mediated MMP-9 expression. Food and Nutrition Research, 2017, 61, 1338918.	2.6	8
38	Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. Journal of Korean Medical Science, 2017, 32, 1496.	2.5	7
39	HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation. PLoS ONE, 2017, 12, e0171860.	2.5	39
40	Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Journal of Korean Medical Science, 2017, 32, 335.	2.5	10
41	MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways. Oncology Reports, 2016, 36, 2313-2320.	2.6	25
42	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	2.5	20
43	MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling cell cycle regulators, and Ets-1-mediated MMP-2 expression. Oncology Reports, 2016, 36, 2421-2429.	2.6	27
44	Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue. International Neurourology Journal, 2016, 20, 122-130.	1.2	12
45	Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal of Korean Medical Science, 2015, 30, 937.	2.5	8
46	p21WAF1 Is Required for Interleukin-16-Induced Migration and Invasion of Vascular Smooth Muscle Cells via the p38MAPK/Sp-1/MMP-9 Pathway. PLoS ONE, 2015, 10, e0142153.	2.5	23
47	Clinical Implications and Prognostic Values of *Prostate Cancer Susceptibility Candidate* Methylation in Primary Nonmuscle Invasive Bladder Cancer. Disease Markers, 2015, 2015, 1-6.	1.3	8
48	Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer. Oncotarget, 2015, 6, 40370-40384.	1.8	20
49	Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. International Neurourology Journal, 2015, 19, 74-84.	1.2	40
50	Role of 1,25-Dihydroxy Vitamin D_3 and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal, 2014, 55, 1326.	2.2	13
51	Effect of Renal Insufficiency on Stone Recurrence in Patients with Urolithiasis. Journal of Korean Medical Science, 2014, 29, 1132.	2.5	13
52	Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal of Korean Medical Science, 2014, 29, 351.	2.5	29
53	Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence. Korean Journal of Urology, 2014, 55, 520.	1.2	3
54	Distinct Metabolic Characteristics and Risk of Stone Recurrence in Patients With Multiple Stones at the First-time Presentation. Urology, 2014, 84, 274-278.	1.0	4

#	Article	IF	Citations
55	The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 458-465.	1.6	9
56	Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology, 2014, 84, 766-771.	1.0	21
57	Decreased *DBC1* Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 631.	1.2	8
58	FAM70Bas a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2012, 53, 598.	1.2	8
59	Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels. Journal of Korean Medical Science, 2011, 26, 1214.	2.5	28
60	Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia. Prostate, 2011, 71, 1210-1215.	2.3	8
61	*GSTT1* as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer. Disease Markers, 2010, 29, 81-87.	1.3	11
62	Identification of C16orf74 as a Marker of Progression in Primary Non-Muscle Invasive Bladder Cancer. PLoS ONE, 2010, 5, e15260.	2.5	13